Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> c-MET

c-MET

c-MET, also called MET, is a membrane receptor that is essential for embryonic development and wound healing.

Products for  c-MET

  1. Cat.No. Product Name Information
  2. GC14729 (R)-Crizotinib

    PF 2341066

     A c-MET and ALK receptor tyrosine kinase inhibitor (R)-Crizotinib Chemical Structure
  3. GC13136 (S)-Crizotinib Potent MTH1 inhibitor (S)-Crizotinib Chemical Structure
  4. GC35095 2-Phospho-L-ascorbic acid trisodium salt 2-Phospho-L-ascorbic acid trisodium salt (2-Phospho-L-ascorbic acid trisodium) is a long-acting vitamin C derivative that can stimulate collagen formation and expression. 2-Phospho-L-ascorbic acid trisodium salt Chemical Structure
  5. GC65894 ABN401 ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC50 value of 10 nM. ABN401 has cytotoxic activity against MET-addicted cancer cells. ABN401 can inhibit c-MET phosphorylation in tumor tissues. ABN401 can be used for researching anticancer. ABN401 Chemical Structure
  6. GC73403 Adrixetinib Adrixetinib is an inhibitor of protein tyrosine kinase with antineoplastic activity. Adrixetinib Chemical Structure
  7. GC16604 Altiratinib

    DCC-2701

     c-MET/TIE-2/VEGFR inhibitor Altiratinib Chemical Structure
  8. GC15655 AMG 337 MET inhibitor AMG 337 Chemical Structure
  9. GC12600 AMG-208 C-Met inhibitor,potent and highly selective AMG-208 Chemical Structure
  10. GC11481 AMG-458

    AMG 458; AMG458

     Potent c-Met inhibitor AMG-458 Chemical Structure
  11. GC16391 Amuvatinib (MP-470, HPK 56)

    HPK56, MP470

     A multi-targeted RTK inhibitor Amuvatinib (MP-470, HPK 56) Chemical Structure
  12. GC33362 Amuvatinib hydrochloride (MP470 hydrochloride)

    MP470 hydrochloride; HPK 56 hydrochloride

     Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity. Amuvatinib hydrochloride (MP470 hydrochloride) Chemical Structure
  13. GC74510 Bafisontamab

    EMB-01

     Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity. Bafisontamab Chemical Structure
  14. GC14214 BMS-777607

    BMS-817378

     BMS-777607 is a pan-TAM inhibitor, which shows anti-tumor activity to different types of cancer. BMS-777607 Chemical Structure
  15. GC13833 BMS-794833 Met/VEGFR-2 inhibitor,potent and ATP-competitive BMS-794833 Chemical Structure
  16. GC17772 BMS-817378 Potent ATP competitive inhibitor of Met/VEGFR2 BMS-817378 Chemical Structure
  17. GC38894 Bozitinib

    PLB-1001; CBT-101; Vebreltinib

     Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. Bozitinib Chemical Structure
  18. GC65966 BPI-9016M BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma. BPI-9016M Chemical Structure
  19. GC19106 c-Kit-IN-1 c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM. c-Kit-IN-1 Chemical Structure
  20. GC35716 c-Met inhibitor 1 c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. c-Met inhibitor 1 Chemical Structure
  21. GC35717 c-met-IN-1 c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity.. c-met-IN-1 Chemical Structure
  22. GC33203 c-Met-IN-2 c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity. c-Met-IN-2 Chemical Structure
  23. GC15779 Cabozantinib (XL184, BMS-907351)

    BMS-907351, Cabozantinib

     Cabozantinib (XL184,BMS-907351) is a novel MET and VEGFR2 inhibitor that simultaneously inhibits metastasis, angiogenesis and tumor growth. Cabozantinib (XL184, BMS-907351) Chemical Structure
  24. GC12531 Cabozantinib malate (XL184) Cabozantinib malate (XL184) (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. Cabozantinib malate (XL184) Chemical Structure
  25. GC73667 Canlitinib Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib Chemical Structure
  26. GC68828 Capmatinib dihydrochloride hydrate

    Capmatinib (INC280; INCB28060) dihydrochloride hydrate is an effective, orally active, selective, ATP-competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit the phosphorylation of c-MET and downstream effectors such as ERK1/2, AKT, FAK, GAB1 and STAT3/5 in the c-MET pathway. Capmatinib dihydrochloride hydrate effectively inhibits proliferation and migration of c-Met-dependent tumor cells and induces apoptosis. It exhibits anti-tumor activity in mouse models of cancer. Capmatinib dihydrochloride hydrate is mainly metabolized by CYP3A4 and aldehyde oxidase.

     Capmatinib dihydrochloride hydrate Chemical Structure
  27. GC72300 Caveolin-1 (82-101) amide (human, mouse, rat) Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs. Caveolin-1 (82-101) amide (human, mouse, rat) Chemical Structure
  28. GC19102 CEP-40783

    RXDX-106

     CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively. CEP-40783 Chemical Structure
  29. GC12616 Crizotinib hydrochloride

    inhibitor of the c-Met kinase and the NPM-ALK

     Crizotinib hydrochloride Chemical Structure
  30. GC64961 CSF1R-IN-2

    CSF1R-IN-2, CSF1R Inhibitor 2, Elzovantinib

     CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively. CSF1R-IN-2 Chemical Structure
  31. GC91419 CYY292 CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC50s = 5.35, 4.6, 28, 28, and 78 nM, respectively). CYY292 Chemical Structure
  32. GC73131 Dalmelitinib Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib Chemical Structure
  33. GC30768 Dihexa (PNB-0408) Dihexa (PNB-0408) (N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide) is an oral active, blood-brain barrier-permeable angiotensin IV analogue. Dihexa (PNB-0408) Chemical Structure
  34. GC62597 DS-1205b free base DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo. DS-1205b free base Chemical Structure
  35. GC10466 EMD-1214063 EMD-1214063 (Tepotinib, MSC2156119J) is a novel potent and highly selective reversible, ATP-competitive small molecule c-Met inhibitor . EMD-1214063 Chemical Structure
  36. GC69058 Emibetuzumab

    LY2875358

    Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 type. Emibetuzumab has high neutralizing and internalizing activity, effectively inhibiting the activation and tumor growth of both HGF-dependent and independent MET pathways. Emibetuzumab can be used for cancer research.

     Emibetuzumab Chemical Structure
  37. GC73405 Emzeltrectinib Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity. Emzeltrectinib Chemical Structure
  38. GC33190 Ensartinib (X-396)

    X-396

     Ensartinib (X-396) (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib (X-396) Chemical Structure
  39. GC32864 Ensartinib hydrochloride (X-396 hydrochloride)

    X-396 dihydrochloride

     Ensartinib hydrochloride (X-396 hydrochloride) (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib hydrochloride (X-396 hydrochloride) Chemical Structure
  40. GC70577 Entacapone acid Entacapone acid (Tyrphostin AG1290) is a tyrosine kinase inhibitor. Entacapone acid Chemical Structure
  41. GC69110 Ficlatuzumab

    Ficlatuzumab is a monoclonal antibody (McAb) that targets human hepatocyte growth factor (HGF). Ficlatuzumab can block the activation of the HGF/c-Met signaling pathway, inhibiting c-Met receptor-mediated cancer cell proliferation, migration and invasion.

     Ficlatuzumab Chemical Structure
  42. GC15735 Foretinib (GSK1363089)

    GSK1363089, XL880

     Foretinib (GSK1363089) is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. Foretinib (GSK1363089) Chemical Structure
  43. GC64708 Fosgonimeton Fosgonimeton Chemical Structure
  44. GC65478 Gemnelatinib Gemnelatinib is a tyrosine kinase inhibitor (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer. Gemnelatinib Chemical Structure
  45. GC19166 Glesatinib hydrochloride

    MGCD265 hydrochloride

     Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. Glesatinib hydrochloride Chemical Structure
  46. GC64947 Glumetinib

    SCC244

     Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity. Glumetinib Chemical Structure
  47. GC17715 Golvatinib (E7050)

    E7050

     Golvatinib (E7050) (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively. Golvatinib (E7050) Chemical Structure
  48. GC17866 INCB28060

    Capmatinib, INC 280

     INCB28060 (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). INCB28060 can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. INCB28060 potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. INCB28060 is largely metabolized by CYP3A4 and aldehyde oxidase. INCB28060 Chemical Structure
  49. GC12585 JNJ-38877605 C-Met inhibitor,ATP-competitive JNJ-38877605 Chemical Structure
  50. GC33266 JNJ-38877618 JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively. JNJ-38877618 Chemical Structure
  51. GC11057 LY2801653

    Merestinib

     A MET kinase inhibitor LY2801653 Chemical Structure
  52. GC73590 MAPK-IN-2 MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 Chemical Structure
  53. GC69460 Mefatinib

    Mifanertinib dimaleate

    Mefatinib is an effective tyrosine kinase inhibitor with anti-tumor activity.

     Mefatinib Chemical Structure
  54. GC69459 Mefatinib free base

    Mifanertinib

    Mefatinib free base is an effective tyrosine kinase inhibitor with anti-tumor activity.

     Mefatinib free base Chemical Structure
  55. GC14951 Meleagrin

    6-O-Methyloxaline

     antibiotic Meleagrin Chemical Structure
  56. GC36585 Merestinib dihydrochloride Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM). Merestinib dihydrochloride Chemical Structure
  57. GC68018 MET kinase-IN-2 MET kinase-IN-2 Chemical Structure
  58. GC74096 MET kinase-IN-4 MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 Chemical Structure
  59. GC13598 MGCD-265 MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity. MGCD-265 Chemical Structure
  60. GC16337 MK-2461 C-Met (WT/mutants) inhibitor MK-2461 Chemical Structure
  61. GC13140 MK-8033

    MK 8033;MK8033

     MK-8033 Chemical Structure
  62. GC36625 MK-8033 hydrochloride MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs). MK-8033 hydrochloride Chemical Structure
  63. GC18211 Ningetinib A multi-kinase inhibitor Ningetinib Chemical Structure
  64. GC36744 Ningetinib Tosylate Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib Tosylate Chemical Structure
  65. GC50152 Norleual

    Highly potent HGF/c-MET inhibitor; also AT4 antagonist

     Norleual Chemical Structure
  66. GC69584 Norleual TFA

    Norleual TFA is a type IV angiotensin (Ang) similar substance and a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. It is also an AT4 antagonist with strong anti-angiogenic activity.

     Norleual TFA Chemical Structure
  67. GC14488 NPS-1034 MET inhibitor NPS-1034 Chemical Structure
  68. GC16972 NVP-BVU972 C-Met inhibitor,potent and selective NVP-BVU972 Chemical Structure
  69. GC69623 Onartuzumab

    MetMAb

    Onartuzumab (MetMAb) is a humanized, affinity-matured monoclonal antibody that inhibits the receptor tyrosine kinase MET. Onartuzumab effectively inhibits HGF binding, receptor phosphorylation and signal transduction. Onartuzumab has antibody-like pharmacokinetics and anti-tumor activity.

     Onartuzumab Chemical Structure
  70. GC12729 PF-04217903 C-Met inhibitor,selective and ATP-competitive PF-04217903 Chemical Structure
  71. GC15733 PF-04217903 methanesulfonate

    PF04217903 mesylate

     A c-Met inhibitor PF-04217903 methanesulfonate Chemical Structure
  72. GC73128 PF-07265807 PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC50 values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 Chemical Structure
  73. GC11733 PHA-665752 C-Met inhibitor,potent and ATP-competitive PHA-665752 Chemical Structure
  74. GC73881 PRO-6E PRO-6E is an oral active PROTAC based on Cereblon ligand, and induces the degradation of MET with maximum degradation of 81.9% at 1 μM in MKN-45 cells. PRO-6E Chemical Structure
  75. GC69817 Rilotumumab

    AMG 102

    Rilotumumab (AMG 102) is a monoclonal antibody that targets the hepatocyte growth factor (HGF), inhibiting HGF/MET-driven signaling. Rilotumumab has anti-tumor activity and is being studied for use in castration-resistant prostate cancer (CRPC) and solid tumors.

     Rilotumumab Chemical Structure
  76. GC73201 Risvodetinib

    IkT-148009

     Risvodetinib (IkT-148009) is an oral, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM. Risvodetinib Chemical Structure
  77. GC19317 S49076 S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. S49076 Chemical Structure
  78. GC33189 SAR125844 SAR125844 is a potent, highly selective, reversible and ATP-competitive MET receptor tyrosine kinase (RTK) inhibitor, with an IC50 of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays. SAR125844 Chemical Structure
  79. GC19321 Savolitinib

    AZD6094, HMPL-504, Volitinib

     Savolitinib (AZD6094) ia highly potent and selective c-Met inhibitor with an IC50 of 5 nM. Savolitinib Chemical Structure
  80. GC19108 SCR-1481B1 SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor. SCR-1481B1 Chemical Structure
  81. GC15664 SGX-523 MET inibitor, highly selective, ATP-competitive SGX-523 Chemical Structure
  82. GC34811 SRI 31215 TFA SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer. SRI 31215 TFA Chemical Structure
  83. GC11089 SU11274

    Met Kinase Inhibitor

     C-Met inhibitor,potent and selective SU11274 Chemical Structure
  84. GC15307 SU5416

    NSC 696819, Semaxinib, Sugen 5416, VEGFR 2 Kinase Inhibitor

     SU5416 is a potent small molecule vascular endothelial growth factor receptor (VEGFR) inhibitor. SU5416 Chemical Structure
  85. GC62268 SYN1143 SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC50s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK with IC50s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated. SYN1143 Chemical Structure
  86. GC33173 TAS-115

    TAS-115

     TAS-115 (TAS-115) is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. TAS-115 Chemical Structure
  87. GC33273 TAS-115 mesylate (TAS-115 methanesulfonate)

    TAS-115 mesylate

     Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. TAS-115 mesylate (TAS-115 methanesulfonate) Chemical Structure
  88. GC63215 Terevalefim

    ANG-3777

     Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor. Terevalefim Chemical Structure
  89. GC14256 Tivantinib (ARQ 197)

    ARQ-197;ARQ197

     Tivantinib (ARQ 197) is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM. Tivantinib (ARQ 197) Chemical Structure
  90. GC70077 Tunlametinib

    Tunlametinib is an anti-tumor compound and a tyrosine kinase inhibitor.

     Tunlametinib Chemical Structure
  91. GC37849 Tyrosine kinase inhibitor Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor. Tyrosine kinase inhibitor Chemical Structure
  92. GC19140 X-376 X-376 is a potent and dual ALK/MET inhibitor with IC50s of 0.61 nM and 0.69 nM, respectively. X-376 Chemical Structure
  93. GC62266 XL092

    XL092

     XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity. XL092 has the potential for kinase-dependent diseases and conditions research. XL092 Chemical Structure
  94. GC11555 ZM 323881 HCl ZM 323881 HCl is a potent and selective VEGFR2 inhibitor with an IC50 of less than 2 nM. ZM 323881 HCl Chemical Structure
  95. GC73202 Zongertinib

    BI 1810631

     Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib Chemical Structure

94 Item(s)

per page

Set Descending Direction